Company Overview
Snapshot
Founded in January 2016 by Or Retzkin, Izhack Davidovich, Itai Kornberg, and Shay Rishoni, EyeControl operates with 11–50 employees. The company has raised $15.21 million across 14 funding rounds from 14 investors. In May 2024, EyeControl secured a grant from Google AI Startup Fund, highlighting ongoing support for its innovative technology.
Business overview
EyeControl is a medical technology company that develops an AI-powered eye-tracking platform to revolutionize ICU care. Its core product, a wearable assistive communication device, enables mechanically ventilated patients to communicate effectively, fostering connections with families and caregivers. The technology provides healthcare teams with actionable insights, supporting evidence-based practices to optimize critical care, enhance patient safety, and improve cognitive and mental health outcomes. EyeControl's device is FDA-listed, CE-marked, ISO-certified, and federally reimbursed in Israel for inpatient and homecare settings, serving the health tech and life sciences sectors.
Strategic signal
In June 2024, EyeControl announced clinical trials in Israel and the US, supported by the Israel-US Binational Industrial Research and Development fund and the NIH AI program, with recent investments from the European Bank and Google's AI Fund. This expansion into clinical trials and strategic funding signals strong market validation and a clear trajectory for global implementation, aiming to significantly reduce ICU delirium and enhance patient care.
Log in to access full profile ›Company Intelligence Q&A
- What was a key development for EyeControl in January 2024?
- In January 2024, EyeControl secured a grant from a2 collective, supporting its continued development in medical technology.
- What strategic partnership did EyeControl announce in June 2024?
- In June 2024, EyeControl announced clinical trials in Israel and the US, partnering with Clalit, Beth Israel Deaconess Medical Center, and Johns Hopkins University to implement its technology in hospitals.
- What was the outcome of EyeControl's Series A funding round in August 2020?
- In August 2020, EyeControl closed a Series A funding round, led by Connecticut Innovations, and secured additional funding from.
- What was EyeControl's engagement with the NHS in October 2018?
- In October 2018, EyeControl's wearable device, designed for patients with locked-in syndrome, became available on the NHS Supply Chain Framework, providing a communication solution for patients in the UK.